Inventor
LOPEZ-GIRONA ANTONIA
US40 patents
⚠️ This page may combine multiple inventors who share the name “LOPEZ-GIRONA ANTONIA”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
CELGENE CORP
31 patentsUS9499514B2Nov 22, 2016
Antiproliferative compounds and methods of use thereof
CELGENE CORP28 citations93
US10357489B2Jul 23, 2019
Antiproliferative compounds and methods of use thereof
CELGENE CORP20 citations92
US10047151B2Aug 14, 2018
Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
CELGENE CORP19 citations92
US10648983B2May 12, 2020
Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies
CELGENE CORP9 citations84
US11185543B2Nov 30, 2021
Antiproliferative compounds and methods of use thereof
CELGENE CORP5 citations82
US10092555B2Oct 9, 2018
Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
CELGENE CORP8 citations82
US9968596B2May 15, 2018
Antiproliferative compounds and methods of use thereof
CELGENE CORP8 citations82
US9808451B2Nov 7, 2017
Antiproliferative compounds and methods of use thereof
CELGENE CORP12 citations82
US9857359B2Jan 2, 2018
Methods for determining drug efficacy using cereblon-associated proteins
CELGENE CORP11 citations81
US10245258B2Apr 2, 2019
Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
CELGENE CORP8 citations80
US11241423B2Feb 8, 2022
Antiproliferative compounds and methods of use thereof
CELGENE CORP2 citations72
US10969381B2Apr 6, 2021
Methods for treating multiple myeloma and the use of companion biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile
CELGENE CORP1 citations72
US11726080B2Aug 15, 2023
Methods for treating multiple myeloma and the use of companion biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile
CELGENE CORP1 citations71
US11666579B2Jun 6, 2023
Methods of treating hematological malignancies using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione
CELGENE CORP2 citations71
US11419861B2Aug 23, 2022
Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
CELGENE CORP1 citations71
US10668057B2Jun 2, 2020
Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
CELGENE CORP3 citations71
US12474342B2Nov 18, 2025
Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies
CELGENE CORP0 citations62
US11460471B2Oct 4, 2022
Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies
CELGENE CORP1 citations62
US12510533B2Dec 30, 2025
Methods for treating multiple myeloma and the use of companion biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile
CELGENE CORP0 citations61
US11945804B2Apr 2, 2024
Substituted 4-aminoisoindoline-1,3-dione compounds, compositions thereof, and methods of treatment therewith
CELGENE CORP0 citations61
US11733233B2Aug 22, 2023
Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
CELGENE CORP0 citations61
US10830762B2Nov 10, 2020
Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
CELGENE CORP1 citations61
US12178822B2Dec 31, 2024
Methods of treating hematological malignancies using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dion
CELGENE CORP0 citations60
US12103923B2Oct 1, 2024
Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione
CELGENE CORP0 citations60
US11390617B2Jul 19, 2022
Methods of treating non-Hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione
CELGENE CORP1 citations60
US11358952B2Jun 14, 2022
Substituted 4-aminoisoindoline-1,3-dione compounds, compositions thereof, and methods of treatment therewith
CELGENE CORP1 citations60
US12029738B2Jul 9, 2024
Antiproliferative compounds and methods of use thereof
CELGENE CORP0 citations59
US11590117B2Feb 28, 2023
Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
CELGENE CORP0 citations59
US12396995B2Aug 26, 2025
Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use
CELGENE CORP0 citations57
US11628172B2Apr 18, 2023
Methods of treating chronic lymphocytic leukemia using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione
CELGENE CORP1 citations57
US11583536B2Feb 21, 2023
Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use
CELGENE CORP0 citations57
SIGNAL PHARM LLC
4 patentsUS9505764B2Nov 29, 2016
Treatment of cancer with dihydropyrazino-pyrazines
SIGNAL PHARM LLC11 citations83
US9493466B2Nov 15, 2016
Treatment of cancer with TOR kinase inhibitors
SIGNAL PHARM LLC7 citations83
US9937170B2Apr 10, 2018
Treatment of cancer with TOR kinase inhibitors
SIGNAL PHARM LLC1 citations62
US9980963B2May 29, 2018
Treatment of cancer with dihydropyrazino-pyrazines
SIGNAL PHARM LLC0 citations51